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ABSTRACT
Objective Western lifestyle and diet are major
environmental factors playing a role in the development
of IBD. Titanium dioxide (TiO2) nanoparticles are widely
used as food additives or in pharmaceutical formulations
and are consumed by millions of people on a daily basis.
We investigated the effects of TiO2 in the development
of colitis and the role of the nucleotide-binding
oligomerisation domain receptor, pyrin domain
containing (NLRP)3 inﬂammasome.
Design Wild-type and NLRP3-deﬁcient mice with
dextran sodium sulfate-induced colitis were orally
administered with TiO2 nanoparticles. The
proinﬂammatory effects of TiO2 particles in cultured
human intestinal epithelial cells (IECs) and macrophages
were also studied, as well as the ability of TiO2 crystals
to traverse IEC monolayers and accumulate in the blood
of patients with IBD using inductively coupled plasma
mass spectrometry.
Results Oral administration of TiO2 nanoparticles
worsened acute colitis through a mechanism involving
the NLRP3 inﬂammasome. Importantly, crystals were
found to accumulate in spleen of TiO2-administered
mice. In vitro, TiO2 particles were taken up by IECs and
macrophages and triggered NLRP3-ASC-caspase-1
assembly, caspase-1 cleavage and the release of NLRP3-
associated interleukin (IL)-1β and IL-18. TiO2 also
induced reactive oxygen species generation and
increased epithelial permeability in IEC monolayers.
Increased levels of titanium were found in blood of
patients with UC having active disease.
Conclusion These ﬁndings indicate that individuals
with a defective intestinal barrier function and pre-
existing inﬂammatory condition, such as IBD, might be
negatively impacted by the use of TiO2 nanoparticles.
INTRODUCTION
The aetiology of IBD remains only partially under-
stood; however, it is now accepted that both
Crohn’s disease (CD) and UC are caused by inter-
play of genetic and environmental factors that
trigger an inappropriate immune response.1 2 The
incidence of IBD is increasing in many nations
undergoing ‘westernisation’, supporting an import-
ant role of environmental factors during IBD
pathogenesis.3 4 Among those environmental
triggers are the increased hygiene and ‘Western
diet’, which includes ingestion of nanoparticles.5 6
Inorganic nanoparticles and microparticles are
used as additives to inﬂuence the appearance of a
dietary product. The most commonly used addi-
tives are submicron-sized (100–1000 nm diameter)
particles of titanium dioxide (TiO2, E171) and alu-
minium silicate (E559). Food and pharma grade
Signiﬁcance of this study
What is already known on this subject?
▸ Titanium dioxide induces reactive oxygen
species (ROS) formation as well as
inﬂammation in vitro and in vivo.
▸ The nucleotide-binding oligomerisation domain
receptor, pyrin domain containing (NLRP)3
inﬂammasome is activated in the presence of
titanium dioxide.
▸ Polymorphisms in the Nlrp3 gene have been
linked to the development of Crohn’s Disease.
What are the new ﬁndings?
▸ Oral administration of titanium dioxide
nanoparticles worsens intestinal inﬂammation
in the dextran sodium sulfate (DSS) mouse
model of colitis.
▸ Titanium dioxide crystals accumulate in the
spleen of DSS-treated mice following oral
gavage.
▸ Titanium dioxide particles accumulate and
activate the NLRP3 inﬂammasome in human
intestinal epithelial cells and macrophages.
▸ Levels of titanium are increased in the blood of
patients with IBD.
How might it impact on clinical practice in
the foreseeable future?
▸ Components of the inﬂammasome may
represent novel therapeutic targets for the
treatment of IBD.
▸ Our results suggest a cautionary use of
titanium dioxide in pharmaceutical formulations
and support a therapeutic beneﬁt from low
inorganic particle diet in patients with IBD.
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TiO2 is found both in its bulk form and as nanoparticle. In fact,
at least 36% of the TiO2 particles present in food consists of
nanoparticles with a particle diameter less than 100 nm.7 The
daily intake of TiO2 was estimated by the European Food Safety
Authorities in 2004 to be 1.28 mg/kg bodyweight.8 Further to
this, in a dietary study assessing the TiO2 consumption of
patients with CD and healthy volunteers Lomer et al9 estimated
that the median individual TiO2 intake in both groups was
2.5 mg/day. A later study estimated a daily intake of TiO2 food
grade of 0.2–2 mg/kg bodyweight,7 evidencing that TiO2 is
ingested in substantial amounts on a daily basis. To date, no
restrictions for the use of TiO2 are enforced by food safety
authorities and only good manufacturing practice guidelines
limit the use of these compounds.10 11 An increasing body of lit-
erature has revealed that exposure to TiO2 can cause adverse
effects, including the production of reactive oxygen species
(ROS),12 inﬂammatory responses and tumour formation.13 In
mice, TiO2 nanoparticles cause genotoxic effects in blood cells,
bone marrow and liver, and DNA deletions in the offspring.14
Cytotoxic effects resulting from TiO2-induced production of
ROS were observed in human lymphoblastoid cells,15 ﬁbro-
blasts, bronchial epithelial cells16 and alveolar macrophages,17
which led to the classiﬁcation of TiO2 as ‘possibly carcinogenic
for humans’. Nanoparticles can accumulate in several organs,
such as kidney, lung, brain, liver and spleen.18 19 In intestinal
biopsies, dark aggregates of TiO2 were detected in M-cells of
Peyer’s patches and in underlying macrophages.20 Interestingly,
these sites of TiO2 uptake correspond to regions where ﬁrst
signs of inﬂammation in patients with CD manifest.21
Nucleotide-binding oligomerisation domain receptor, pyrin
domain containing (NLRP)3 is a member of the Nod-like recep-
tor (NLR) family that regulates the activation of caspase-1 by
forming signalling complexes called ‘inﬂammasomes’. On acti-
vation, NLRP3 binds to the apoptosis-associated speck-like
protein containing a caspase recruitment domain (ASC) adapter
protein, which in turn recruits and activates caspase-1. Activated
caspase-1 cleaves pro-interleukin (IL)-1β and pro-IL-18 into
their biologically active forms.22 23 Single nucleotide poly-
morphisms in the Nlrp3 gene have been linked to the develop-
ment of CD.24 NLRP3 has been shown to be activated by a
wide range of pathogens and intrinsic danger signals like ATP,25
ROS, crystalline monosodium urate,26 cholesterol crystals27 and
inorganic materials like aluminium salts,28 asbestos and silica
crystals.29 Similarly, inorganic TiO2 nanoparticles activate the
NLRP3 inﬂammasome and induce a proinﬂammatory response
in human keratinocytes, human dendritic cells and murine
macrophages.23
In the present study, we analysed the effect of TiO2 on intes-
tinal inﬂammation as well as the contribution of the NLRP3
inﬂammasome in TiO2-mediated inﬂammatory responses. For
this purpose, we used the dextran sodium sulfate (DSS) acute
colitis model in the wild-type (WT) and NLRP3-deﬁcient
(Nlrp3−/−) mice. Oral administration of TiO2 nanoparticles
worsened intestinal inﬂammation through NLRP3. Moreover,
crystals were found to accumulate in splenic tissue of
TiO2-administered mice, but not in those receiving water. In
vitro experiments showed that both TiO2 nanoparticles and
food grade TiO2 microparticles trigger proinﬂammatory cyto-
kine secretion through NLRP3 inﬂammasome activation, and
accumulate in human intestinal epithelial cells (IECs) and
macrophages. TiO2 particles induced ROS production in IECs
and increased epithelial permeability. Finally, an increase of
titanium burden in blood of patients with UC having active
disease was found, evidencing an impaired barrier function and
suggesting that TiO2 nanoparticles could pose a speciﬁc risk to
patients with IBD.
MATERIAL AND METHODS
Mouse experiments
Acute colitis was induced in female WT (C57BL/6J) and
Nlrp3−/− mice between 12 and 14 weeks of age by oral adminis-
tration of 1.5% DSS30 (MP Biomedicals) in drinking water ad
libitum for 7 days. A suspension of TiO2 nanoparticles (rutile,
30–50 nm, IoLiTec) in drinking water was administered daily by
oral gavage. WT mice were divided in three groups of 12 mice
each, and received water, 50 or 500 mg TiO2/day/kg body-
weight. Nlrp3−/− mice received water (n=10) or 500 mg TiO2/
day/kg bodyweight (n=10). On day 8, colitis was assessed by
endoscopy and mice were sacriﬁced for sample collection. All
the animal experiments were approved by the veterinary author-
ities of Zurich, Switzerland.
Colonoscopy and determination of histological score
Animals were anaesthetised intraperitoneally with a mixture of
ketamine 90–120 mg/kg bodyweight (Vétoquinol) and xylazine
8 mg/kg bodyweight (Bayer), and colonoscopy was performed
as described previously.31 Animals were sacriﬁced and colon
length was measured. About 1 cm of tissue was removed from
the distal third of the colon and ﬁxed in 4% formalin overnight.
H&E stained sections of the parafﬁn-embedded tissue were
used for histological analysis. Histological score was determined
as described previously32 33 by two independent, blinded
investigators.
Western blotting and co-immunoprecipitation
Total protein from cell monolayers was harvested into M-PER
lysis buffer (Thermo Fisher Scientiﬁc) and western blotting was
performed to determine the expression of NLRP3 (Enzo life
sciences), caspase-1, ASC, IL-1β (Cell Signaling Technologies)
and IL-18 (MBL). Co-immunoprecipitation (Co-IP) was
performed overnight at 4°C using NLRP3 antibody.
Immunocomplexes were collected with Protein G Sepharose
beads (GE Healthcare) for 1 h at 4°C prior to western blotting.
Microscopy of spleen cryosections and Caco-2 monolayers
Confocal reﬂection microscopy was combined with ﬂuorescence
microscopy in a Leica SP8 laser scanning confocal microscope, as
described previously.28 Caco-2 cells grown on coverslips and
transwells were ﬁxed with 4% PFA for 20 min. Coverslips were
directly subjected to H&E staining. Cryosections of transwells
with Caco-2 monolayers were cut at cryogenic temperatures at
5–20 μm thickness. Sections were stained with H&E or
DAPI-containing mounting medium (Vector Laboratories) and
images were captured using a ﬂuorescent microscope (Axioplan2,
Zeiss). For electron microscopy, Caco-2 cells were ﬁxed and
embedded in Epon according to established protocols.34 Electron
microscopic analysis, including elemental analysis was performed
with a CM12 electron microscope (FEI) equipped with an EDX
detector (Genesis, EDAX). For quantiﬁcation of intracellular
microparticles, 5 μm sections of TiO2-stimulated Caco-2 mono-
layers grown on transwell membranes were used. Particles and
aggregates of TiO2 were counted in phase-contrast view, and
DAPI-stained nuclei were counted in blue ﬂuorescent channel.
Cell culture and reagents
THP-1 cells were maintained in RPMI medium (Invitrogen)
supplemented with 10% fetal calf serum (VWR). To induce
differentiation, 40 nM phorbol-12-myristate-13-acetate (Sigma-
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Aldrich) was added to 0.5×106 cells/mL. Caco-2 and HT-29
were obtained from the German Collection of Cells and
Microorganisms (DSMZ). Other IEC lines were provided and
previously described35 by the Department of Internal Medicine
Regensburg and cultured under conditions as recommended by
the DSMZ. Inﬂammasome activation was triggered in IECs with
crude lipopolysaccharide (Santa Cruz) at a concentration of
10 μg/mL. TiO2 (AHRSE; geometric particle size of ca 0.36 μm,
PSD of around 1.35), an uncoated anatase of high purity used
in cosmetics and food, was obtained from Huntsman Pigments.
Particles were sterilised by addition of 1 mL 70% ethanol to
20 mg TiO2 and by subsequently vacuum freeze-drying.
Particles were resuspended in ultrapure water and sonicated for
5 min to obtain a homogenous suspension.
Isolation and stimulation of bone marrow-derived
macrophages
Mononuclear phagocyte progenitor cells were ﬂushed from
femural and tibial bones from C57/BL6 mice with cell culture
medium. After centrifugation, cells were resuspended in medium
containing 30 ng/mL recombinant murine macrophage-
stimulating factor (Biovision) and kept for 5 days before stimula-
tion with 20 μg/mLTiO2 and 5 μM cytochalasin D (Invivogen).
ELISA analysis
ELISAs directed against active forms of IL-1β (R&D Systems)
and IL-18 (MBL) were conducted with cell culture supernatants
according to manufacturer’s instructions.
Small interfering RNA knockdown of inﬂammasome
components
Undifferentiated THP-1 cells were transfected with three sets of
small interfering RNAs (siRNAs) for caspase-1, ASC and
NLRP3 at a concentration of 100 pmol each, and electroporated
using the Amaxa nucleofector kit (Mirus Bio LLC) following
manufacturer’s instructions.
Assessment of lysosomal integrity
Caco-2 and HT-29 cells were stained with 1 mg/mL acridine
orange (Sigma-Aldrich) for 15 min prior to TiO2 and cytochala-
sin D stimulation. Lysosomal rupture was analysed by ﬂuores-
cent microscopy (Axioplan2, Zeiss).
Measurement of ROS production
IECs were incubated with Hank’s balanced salt solution (HBSS)
(Sigma-Aldrich) containing 50 μM of dihydro-dichloroﬂuorescin
diacetate (Sigma-Aldrich) for 30 min at 37°C. ROS-induced
ﬂuorescence was detected using a microplate reader with an
excitation wavelength of 485 nm and an emission wavelength of
528 nm.
Epithelial permeability studies
Caco-2 cells were grown as monolayers on transwell membranes
as described above. Flux of ﬂuorescein isothiocyanate-dextran
beads (average molecular weight 40 000, Sigma-Aldrich) was
measured 2 h after addition of 1 mg/mL beads to the apical
compartment. Fluorescence intensity in aliquots from the baso-
lateral compartment was measured using a microplate reader
with an excitation wavelength of 485 nm and an emission wave-
length of 525 nm.
Human subjects
The study was conducted as a subproject of the Swiss IBD
Cohort Study and was approved by the Ethics Committees (EK
1316).36 Prior to inclusion into the study, written informed
consent was obtained from all patients. Inclusion criteria for
enrolment of patients with IBD having active disease were
18–80 years of age and at least one episode of active disease
between 1 September 2010 and 31 August 2011. Flare-up epi-
sodes reported by the patient were veriﬁed by a physician in the
course of a clinical examination. Inclusion criteria for enrolment
of patients with IBD in clinical remission were 18–80 years of
age and maintenance of clinical remission between 1 September
2010 and 31 August 2011. Exclusion criteria in this study were
perianal CD and positive results of microbiological workup of
faecal samples for known infectious agents. Clinical activity in
patients with CD and patients with UC was assessed using the
Harvey Bradshaw Index (HBI)37 and the Rachmilewitz Index,38
respectively. A ﬂare-up episode in patients with CD was deﬁned
as a rise in HBI value of ≥4 points. A ﬂare-up in patients with
UC was deﬁned as an increase in the Rachmilewitz Index value
of ≥5 points. Titanium levels in blood samples from healthy
volunteers (n=28), patients with UC having active disease
(n=5), patients with UC in remission (n=6), patients with CD
having active disease (n=8) and patients with CD in remission
(n=9) were measured by inductively coupled plasma mass spec-
trometry (ICP-MS) at the Department of Forensic Pharmacology
and Toxicology of the University of Zurich, Switzerland.
Inductively coupled plasma mass spectrometry
Sample preparation for ICP-MS
All calibration standard solutions were prepared from 1 mg/mL
single element standard solutions (Merck) by dilution with ultra-
pure water. About 0.5 mL of whole blood from patients was
diluted in 4.5 mL ultrapure water and infused into the ICP-MS.
Seronorm trace elements whole blood samples (level 3; titanium
concentration: 24 mg/L; accepted range 20–28 mg/L) were pre-
pared in the same manner as the whole blood samples from
patients and used as control (SERO AS).
ICP-MS
AVarian ICP-MS 810 (low resolution) equipped with type 142
Varian cooler and a Varian SPS 3 Autosampler (Varian) were used
with the following measurement parameters: analysis type: quan-
titative; acquisition mode: steady state; scan mode: peak
hopping; spacing: coarse; points/peak: 1; scans/replicate: 50;
replicates/sample: 3; plasma ﬂow: 18.00 L/min; auxiliary
ﬂow: 1.75 L/min; sheath gas ﬂow: 0.24 L/min; nebuliser ﬂow:
1.00 L/min; sampling depth: 5.00 mm; power: 1.35 kW; pump
rate: 7 rpm; stabilisation delay 0 s; ion optics (volt) version
number: 0; ﬁrst extraction lens: −1.00; second extraction
lens: −129.00; third extraction lens: −214.00; left mirror lens:
32.00; right mirror lens: 17.00; bottom mirror lens: 28.00;
corner lens: −199.00; entrance lens: −1.00; fringe bias:
−4.50; entrance plate: −32.00; detector focus: true pole
bias: 0.00; sampling aerosol generation: nebuliser, source: auto-
sampler; fast pump during sample delay/rinse: On; probe height:
0 mm; premix: Off; rinse time: 10 s; spray chamber cooling: on
spray chamber temperature: 3.00°C; sample uptake delay: 50 s;
smart rinse: No; switch delay: OFF; scan time: 1415 ms; repli-
cate time: 70.75 s; titanium isotope for quantiﬁcation: 49. All
chemicals (eg, water, acid, hydrogen peroxide) and materials (eg,
tubes, blood Monovettes including needles) were checked for
interferences. All results were under the detection limit of the
procedure (0.25 mg/L). Calibration was done in every series,
using standard solutions of 1, 10 and 100 mg/L Titanium and a
blank. The results of the Seronorm quality control samples were
very good. Mean (n=14) of the results of the Seronorm control
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level 3 (target value 24 mg/L) was 24.5 mg/L with a coefﬁcient of
variation of 9.6%. Thus, the method was more than suitable for
our purposes, especially considering that, while accuracy may be
marginally compromised, relative differences between the groups
should stay the same.
Statistics
Statistical analysis was performed using Student’s t test, Mann–
Whitney test or one-way analysis of variance with Dunnett’s
post-test. The results are expressed as mean±SEM and signiﬁ-
cance was set as p<0.05.
RESULTS
Administration of TiO2 nanoparticles aggravates
DSS-induced colitis
To study the impact of TiO2 nanoparticles in colitis, and the
role of NLRP3 inﬂammasome in TiO2-mediated effects,
DSS-treated WT and Nlrp3−/− mice were administered with 0,
50 or 500 mg/kg/day TiO2 nanoparticles by oral gavage. WT
mice receiving TiO2 presented a more severe colitis than mice
receiving TiO2-free drinking water, as evidenced by a signiﬁcant
shortening of the colon (ﬁgure 1A), and colonoscopy results
(ﬁgure 1B). In contrast, Nlrp3−/− mice administered with
500 mg/kg/day TiO2 showed no differences in colon length or
colonoscopy ﬁndings compared with WT and Nlrp3−/− mice
receiving water (ﬁgure 1A,B). Similarly, H&E stained sections of
colonic tissue presented a signiﬁcantly higher inﬂammatory cell
inﬁltration (ﬁgure 1C) and total histological score with a severe
disruption of the mucosal epithelium in TiO2-treated WT, but
not Nlrp3−/− mice (ﬁgure 1D,E). Mice receiving TiO2 in the
absence of colitis did not present shortening of the colon, or
increased histological scores (data not shown), suggesting that
TiO2 might be deleterious only in pre-existing inﬂammation.
Recent studies have shown that, after intravenous injection of
TiO2 in rats, signiﬁcant levels of TiO2 in spleen and liver were
still found 30 days post injection.39 When applied intraperitone-
ally in mice, TiO2 was distributed throughout the entire body
but was mainly retained in liver and spleen.40 In our experimen-
tal setting, analysis of splenic cryosections using a combination
of confocal and reﬂexion microscopy revealed that oral adminis-
tration of TiO2 led to the accumulation of crystals in the spleen
of DSS-treated mice in a dose-dependent manner (ﬁgure 1F).
TiO2 induces NLRP3 activation and caspase-1 downstream
effectors in human IECs and macrophages
Since IECs have rarely been used in NLRP3 inﬂammasome
studies, protein expression of NLRP3 was conﬁrmed by western
blot in human IEC lines (see online supplementary ﬁgure S1A).
Interestingly, both nanoparticles and microparticles induced
IL-1β secretion in the monocytic cell line THP-1 (ﬁgure 2A), as
well as caspase-1 cleavage (ﬁgure 2B) and IL-1β cleavage (ﬁgure
2C) in both Caco-2 and THP-1 cells. Co-IP of NLRP3 further
evidenced the association of the inﬂammasome components
caspase-1, ASC and NLRP3 on stimulation with both TiO2
Figure 1 Administration of titanium dioxide (TiO2) nanoparticles aggravates colitis in the dextran sodium sulfate (DSS) mouse model of acute
colitis through activation of the nucleotide-binding oligomerisation domain receptor, pyrin domain containing (NLRP)3 inﬂammasome. (A–E)
DSS-treated wild-type (WT) and Nlrp3−/− C57BL/6J mice received TiO2 by oral gavage as indicated. Mice were sacriﬁced at day 8 and colon length
was measured (A). Mucosal damage was assessed by colonoscopy (B). H&E staining of sections displayed severe barrier breakdown (C) with
extensive inﬁltration reaching the lamina muscularis mucosae (D). Total histological score was calculated as the sum of epithelial damage and
inﬁltration score (E). Results represent mean±SEM; WT mice: n=12, Nlrp3−/− mice: n=10, *p<0.05; **p<0.01; ***p<0.001. (F) Cryosections of
spleen from DSS-treated WT mice administered with TiO2 or TiO2-free water were ﬁxed and nuclei were stained with DAPI (blue). The presence of
crystals (red) was analysed combining confocal reﬂection microscopy with ﬂuorescence microscopy. Results are representative of four experiments.
Scale bars: 10 μm.
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crystal forms (ﬁgure 2D). TiO2 microparticles induced IL-18
cytokine secretion in Caco-2 and THP-1 cells (ﬁgure 2E,F).
Moreover, siRNA knockdown of the inﬂammasome compo-
nents NLRP3, ASC and caspase-1 in THP-1 cells signiﬁcantly
reduced the levels of IL-1β in the presence of TiO2 demonstrat-
ing that TiO2-induced IL-1β release is NLRP3 inﬂammasome-
dependent (ﬁgure 2G).
TiO2 accumulates in human IECs and macrophages in a
dose-dependent manner
In agreement with previous reports,23 incubation of THP-1 cells
with food grade TiO2 microparticles led to intracellular accumu-
lation of dark aggregates (ﬁgure 3A). Additionally, we observed
that TiO2 was taken up by murine BMDMs (ﬁgure 3B).
Pretreatment of BMDMs with cytochalasin D, an inhibitor of
endocytosis, did not inhibit the accumulation of TiO2 aggregates
(ﬁgure 3C), pointing to an endocytosis-independent uptake
mechanism. As the intestinal epithelium is subjected to the
major exposure to TiO2, we investigated whether TiO2 also
penetrates IECs. Treatment of monolayers of the IEC lines
HT-29 and Caco-2 with TiO2 microparticles for 24 h resulted
in intracellular accumulation of TiO2 (ﬁgure 3D,E). To mimic
the physiological setting in the intestine, tight monolayers of
Caco-2 cells growing on transwell ﬁlters were stimulated apically
with TiO2. Cross-sections of these monolayers revealed dark,
intracellular aggregates of microparticles (ﬁgure 4A,B), which
were present in a dose-dependent manner (ﬁgure 4C,D). These
ﬁndings were conﬁrmed by electron microscopy: TiO2 was
detectable in cross-sections of Caco-2 monolayers as electron
dense aggregates (ﬁgure 4E) and elemental analysis of selected
areas conﬁrmed that aggregates contained titanium (ﬁgure 4F).
TiO2 triggers ROS production and epithelial permeability
in IECs
The uptake of TiO2 particles has been associated with the pro-
duction of ROS,16 which are major inducers of NLRP3 inﬂam-
masome activation via stress-associated signals.41 Our results
show that TiO2 microparticles induced ROS production in
HT-29 (ﬁgure 5A) and Caco-2 cells (ﬁgure 5B) in a dose-
dependent manner. Particulate matter has been shown to induce
inﬂammasome activation through lysosomal rupture following
endocytosis.28 To investigate whether this is also the case with
TiO2 microparticles, lysosomal staining with acridine orange
was performed on IECs stimulated with TiO2. Fluorescence
microscopy did not show any loss of lysosomal integrity in
TiO2-treated Caco-2 and HT-29 cells (see online supplementary
ﬁgure S2A–C). Based on our results showing intracellular accu-
mulation of TiO2 in epithelial monolayers, we sought to
Figure 2 Caspase-1 downstream effectors are activated in macrophages and intestinal epithelial cells (IECs) on exposure to titanium dioxide
(TiO2). (A) THP-1 cells were treated for 24 h with indicated amounts of TiO2 nanoparticles and microparticles, and the secretion of active interleukin
(IL)-1β in cell culture supernatants was assessed by ELISA (n=3, **p<0.01, ***p<0.001). (B–D) Caco-2 and THP-1 cells were treated for 24 h with
indicated amounts of TiO2 nanoparticles and microparticles. The activation of caspase-1 (B) and IL-1β (C) in response to 5 μg/mL TiO2 was
detectable in both cell lines. Lysates were subjected to co-immunoprecipitation (Co-IP) using nucleotide-binding oligomerisation domain receptor,
pyrin domain containing (NLRP)3-antibody prior to western blotting to detect caspase-1 and ASC (D). (E–G) Incubation of Caco-2 (E) with TiO2
microparticles resulted in release of active IL-18 in cell supernatants (n=4). In THP-1 cells, release of both IL-18 (F) and IL-1β (G) was signiﬁcantly
increased on stimulation with TiO2 microparticles (n=3, ***p<0.001), an effect that was dependent on the presence of inﬂammasome components.
Small interfering RNA (siRNA)-mediated knockdown of ASC, NLRP3 or caspase-1 in THP-1 cells resulted in signiﬁcantly lower levels of IL-1β on TiO2
stimulation (G) (n=3, ***p<0.001).
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investigate the effects of TiO2 on epithelial permeability. For
this purpose, we used the transwell model system with Caco-2
cells, which form tight monolayers with an apical-basolateral
polarity. The treatment of Caco-2 with 20 μg/mL TiO2 resulted
in a signiﬁcant increase of epithelial permeability (ﬁgure 5C).
Patients with UC having active disease present increased
levels of titanium in systemic circulation
Given the increased permeability in the mucosa of patients with
IBD, and based on our ﬁndings showing the proinﬂammatory
effects of food-derived TiO2 and its ability to traverse the intes-
tinal mucosa in vivo, we hypothesised that patients with IBD
may have a higher systemic burden of titanium. Using ICP-MS,
we assessed the levels of titanium in whole blood of healthy
donors and patients with IBD. Initial data analysis did not reveal
signiﬁcant differences in titanium levels when comparing
healthy donors with patients with IBD (ﬁgure 6A). However,
we observed signiﬁcantly higher titanium levels in the subgroup
of patients with UC having active disease (ﬁgure 6B).
DISCUSSION
Our results show that oral administration of TiO2 nanoparticles
enhances intestinal inﬂammation in the DSS mouse model of
colitis. Although TiO2 concentrations used are higher than the
amounts the human gut is daily exposed to, the results obtained
suggest that TiO2 is biologically active and support a growing
body of literature evidencing the deleterious effects of TiO2
in vivo.12 42–44 TiO2 proinﬂammatory effects required NLRP3
inﬂammasome activation as shown when comparing WT with
Nlrp3−/− mice. The role of NLRP3 in DSS colitis is controver-
sial with reports showing detrimental45 46 and protective47 48
roles for NLRP3. In our study, 1.5% DSS induced a mild
inﬂammation in WT and Nlrp3−/− mice and we did not detect
signiﬁcant differences between the two groups. Despite the rela-
tively large consumption of TiO2, stability and aggregation in
GI ﬂuids has received limited attention. Recent studies using in
vitro human digestion models have shown that SiO2 and Ag
nanoparticles, which agglomerated under conditions of low pH
and high electrolytes as in the gastric compartment, become bio-
available under intestinal conditions.49 50 Our mouse experi-
ments demonstrate a dose-dependent accumulation of crystals in
the spleen, pointing to the fact that ingested TiO2 can traverse
the intestinal mucosa and reach the systemic circulation. This
ﬁnding agrees with recent studies showing that TiO2 nanoparti-
cles translocate through the intestinal epithelium and accumulate
in the spleen in orally administered mice.51 52 Of note, we
could not ﬁnd accumulation of TiO2 crystals in the colonic epi-
thelium, suggesting that TiO2 nanoparticles are mostly absorbed
in the small intestine. This is in accordance with previous
studies showing that TiO2 particles translocate through the epi-
thelium lining the small intestine, in particular Peyer’s
patches.20 51 We show that TiO2 nanoparticles and microparti-
cles induce NLRP3-ASC-caspase-1 assembly and caspase-1
cleavage, resulting in the release of functionally active IL-1β in
Caco-2 and THP-1 cells in the absence of other stimulus. TiO2
microparticles also induced IL-18 secretion in both cell lines.
Since TiO2 microparticles contain a signiﬁcant amount of nano-
sized particles, it is likely that the effects observed on micropar-
ticle stimulation are due, at least in part, to the presence of
TiO2 nanoparticles. Knockdown of NLRP3, ASC and caspase-1
abrogated TiO2-induced IL-1β expression in macrophages, evi-
dencing the crucial role of the NLRP3 inﬂammasome in
TiO2-mediated proinﬂammatory responses. In vitro experiments
showed that TiO2 microparticles are taken up by human non-
phagocytic IECs as well as macrophage-like THP-1 cells. In
agreement with previous reports showing that TiO2 particles
can enter cells via non-endocytic mechanisms,53 our results
point to that TiO2 uptake was not endocytosis-mediated, and
no speciﬁc subcellular structure was found to be associated with
TiO2 accumulations. Moreover, we did not observe an involve-
ment of lysosomal structures or TiO2-induced lysosomal
damage, suggesting that TiO2 particles might interact with lipid
membranes and are passively transported into cells, as seen with
silica nanoparticles.54 TiO2 particles were shown to disturb
Figure 3 Aggregates of titanium dioxide (TiO2) accumulate
intracellularly in macrophages and intestinal epithelial cells (IECs). (A)
After 24 h incubation with 100 mg/mL TiO2, THP-1 cells were ﬁxed and
stained with eosin. Arrows indicate intracellular TiO2 aggregates. Scale
bars: 100 μm. (B and C) BMDM were stimulated with 20 μg/mL TiO2,
without (B) or with cytochalasin D (C) for 24 h, and images of live
cultures were taken. TiO2 aggregates can be found in all cells, and they
show a distinct distribution pattern (arrows). Inhibition of endocytosis
with cytochalasin D did not abolish the uptake of TiO2. (D and E)
HT-29 (D) and Caco-2 (E) cells were grown on glass cover slips and
incubated with 100 mg/mL TiO2 for 24 h. Intracellular aggregates of
TiO2 were found in both cell types, indicated by arrows. Scale bar:
100 mm.
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epithelial barrier function in Caco-2 monolayers. Although
small, this effect hints to an inﬂuence of TiO2 in epithelial per-
meability, and is in accordance with studies showing that TiO2
nanoparticles induce tight junction remodelling in the intestinal
epithelium of mice.51 Mimicking human gut exposure to TiO2
particles in vitro meets often with difﬁculties: as TiO2 particles
are in an aqueous suspension, they tend to precipitate forming
blankets by the end of the incubation time. This might nega-
tively affect cellular responses on TiO2 stimulation, especially at
high concentrations. The detection of signiﬁcant ROS produc-
tion in TiO2-stimulated IECs is in line with previous studies
showing that uptake of particulate matter is accompanied by
ROS production and inﬂammasome activation.29 55 Strikingly,
ICP-MS analysis revealed increased levels of titanium in the
blood of patients with UC having active disease, pointing to that
the disturbed barrier function associated with IBD allows for a
higher translocation of TiO2 nanoparticles into the systemic
blood stream. Absorbed TiO2 might enhance inﬂammation and
barrier permeability, facilitating further TiO2 penetration on
subsequent exposures. This would support the suggested thera-
peutic beneﬁt from low inorganic particle diet observed in
patients with IBD. For example, the reduction of nano and
microparticles in the diet of patients with CD signiﬁcantly
decreased their disease activity within a month of treatment.56
In contrast, a posterior multi-centered follow-up with 83
patients with CD did not show any effect of a microparticle free
diet.57 However, in this trial dietary calcium was also restricted,
and effects may have been masked by the corticosteroid treat-
ment received by the participants of the study.
In summary, these ﬁndings show that orally administered
TiO2 nanoparticles worsen intestinal inﬂammation in mice
through the activation of NLRP3 inﬂammasome. TiO2 is one of
Figure 4 Aggregates of titanium dioxide (TiO2) accumulate intracellularly in Caco-2 cells in a dose-dependent manner. (A and B), Caco-2 cells
grown on transwells were incubated with 100 mg/mL TiO2 for 24 h. Cross-sections were stained with H&E (A) or DAPI to visualise nuclei and the
same frame was observed in phase-contrast view to identify TiO2 aggregates (B). Scale bar: 25 mm. TiO2 aggregates were located intracellularly in
aggregates of various sizes, indicated by arrows. (C–F) Cross-sections were processed as described above, and TiO2 aggregates and nuclei were
counted. Incubation of Caco-2 for 24 h with indicated amounts of TiO2 resulted in a dose-dependent increase of intracellular TiO2 (C). The size of
TiO2 aggregates also increased in a dose-dependent manner. Electron dense regions with a diameter larger than 3.5 mm were considered as large
aggregates (D). Cross-sections were subjected to transmission electron microscopy, revealing electron-dense aggregates indicated by arrows (E). The
elemental analysis of a selected region (indicated as asterisk in panel E) conﬁrmed that aggregates contained titanium, which appeared as main
peak at 4.5 keV (indicated by arrow) (F).
Figure 5 Titanium dioxide (TiO2) triggers production of reactive oxygen species (ROS) and inﬂuences epithelial permeability in human intestinal
epithelial cells (IECs). (A and B) HT-29 showed signiﬁcantly increased production of ROS at the highest dose of 100 μg/mL of TiO2 (A). In Caco-2
cells, a signiﬁcant increase of ROS was detected at TiO2 concentrations of 20 and 100 μg/mL (B). (C) Monolayers of Caco-2 cells were treated with
indicated amounts of TiO2 for 24 h, and incubated apically with FITC-labelled beads for 1 h. An increase of basolateral ﬂuorescence was observed in
TiO2-treated cells as compared with non-treated cells (n=5, **p<0.05).
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the most produced nanomaterials in the world and its use as
food additive is on the rise. Since TiO2 is also used in pharma-
ceutical formulations, local luminal concentrations of TiO2
might reach substantial levels. Depending on the properties of
the pills, they disintegrate at different sections of the GI tract
and can affect the epithelium in a very distinct and concentrated
manner. A local accumulation of TiO2 may have profound
effects on patients with a disturbed barrier function as found in
IBD. Very high concentrations of particles are often chosen in
toxicity studies to ensure bioactivity across the assays evaluated.
Hence, there is a pressing need for biologically relevant human
exposure information to facilitate interpretation of assay results.
Since the long-term effects of dietary TiO2 may be revealed
only in decades, after a lifetime exposition to TiO2, our data
suggest a more cautious use of these particles.
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